Literature DB >> 8655978

Factors affecting treatment responses to interferon-alpha in chronic hepatitis C.

J M Pawlotsky1, F Roudot-Thoraval, A Bastie, F Darthuy, J Rémiré, J M Métreau, E S Zafrani, J Duval, D Dhumeaux.   

Abstract

Parameters have been studied to predict responses to interferon (IFN) therapy for chronic hepatitis C, but the definition of a response, the times at which responses were assessed, and the pretreatment parameters considered differ markedly from study to study. Thus, 113 patients with chronic hepatitis C were treated 3-6 months with 3 MU of IFN-alpha 2a three times a week and assessed for pretreatment parameters predictive of responses to IFN. In a multivariate analysis, a biochemical response (normal aminotransferase activity) at the end of treatment was significantly associated with low body weight, normal gamma-glutamyl transpeptidase activity, and a pretreatment hepatitis C virus (HCV) genotype other than 1. Six months after the end of treatment, a low virus burden and a lack of anti-HCV IgM core antibodies were independently associated with sustained virologic response (i.e., normal aminotransferase activity and HCV RNA negativity). Therefore, these pretreatment parameters should be taken into account when individual treatment protocols are designed.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8655978     DOI: 10.1093/infdis/174.1.1

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  15 in total

1.  Conservation of the conformation and positive charges of hepatitis C virus E2 envelope glycoprotein hypervariable region 1 points to a role in cell attachment.

Authors:  F Penin; C Combet; G Germanidis; P O Frainais; G Deléage; J M Pawlotsky
Journal:  J Virol       Date:  2001-06       Impact factor: 5.103

2.  Association of pretreatment serum interferon gamma inducible protein 10 levels with sustained virological response to peginterferon plus ribavirin therapy in genotype 1 infected patients with chronic hepatitis C.

Authors:  M Diago; G Castellano; J García-Samaniego; C Pérez; I Fernández; M Romero; O L Iacono; C García-Monzón
Journal:  Gut       Date:  2005-09-08       Impact factor: 23.059

3.  High-affinity aptamers to subtype 3a hepatitis C virus polymerase display genotypic specificity.

Authors:  Louisa A Jones; Leighton E Clancy; William D Rawlinson; Peter A White
Journal:  Antimicrob Agents Chemother       Date:  2006-09       Impact factor: 5.191

4.  Cyclosporin A inhibits hepatitis C virus replication and restores interferon-alpha expression in hepatocytes.

Authors:  J-P Liu; L Ye; X Wang; J-L Li; W-Z Ho
Journal:  Transpl Infect Dis       Date:  2010-10-07       Impact factor: 2.228

5.  Basic residues in hypervariable region 1 of hepatitis C virus envelope glycoprotein e2 contribute to virus entry.

Authors:  Nathalie Callens; Yann Ciczora; Birke Bartosch; Ngoc Vu-Dac; François-Loïc Cosset; Jean-Michel Pawlotsky; François Penin; Jean Dubuisson
Journal:  J Virol       Date:  2005-12       Impact factor: 5.103

6.  Inhibition of kinases impairs neutrophil activation and killing of Staphylococcus aureus.

Authors:  B Schnyder; P C Meunier; B D Car
Journal:  Biochem J       Date:  1998-04-15       Impact factor: 3.857

Review 7.  A brief history of the treatment of viral hepatitis C.

Authors:  Doris B Strader; Leonard B Seeff
Journal:  Clin Liver Dis (Hoboken)       Date:  2012-03-06

8.  Serological determination of hepatitis C virus genotype: comparison with a standardized genotyping assay.

Authors:  J M Pawlotsky; L Prescott; P Simmonds; C Pellet; P Laurent-Puig; C Labonne; F Darthuy; J Remire; J Duval; C Buffet; J P Etienne; D Dhumeaux; E Dussaix
Journal:  J Clin Microbiol       Date:  1997-07       Impact factor: 5.948

9.  Hepatitis C virus (HCV) core antigen assay to detect ongoing HCV infection in thai injection drug users.

Authors:  Dale M Netski; Xiao-Hong Wang; Shruti H Mehta; Kenrad Nelson; David Celentano; Satawat Thongsawat; Niwat Maneekarn; Vinai Suriyanon; Jaroon Jittiwutikorn; David L Thomas; John R Ticehurst
Journal:  J Clin Microbiol       Date:  2004-04       Impact factor: 5.948

10.  High-throughput real-time reverse transcription-PCR quantitation of hepatitis C virus RNA.

Authors:  M Martell; J Gómez; J I Esteban; S Sauleda; J Quer; B Cabot; R Esteban; J Guardia
Journal:  J Clin Microbiol       Date:  1999-02       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.